Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04225117 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
A Phase 2 study of Locally Advanced or Metastatic Malignant Solid Tumors, sponsored by Astellas Pharma Global Development.
- Active
- Registry status
- Phase 2
- Development phase
- 329
- Enrollment target
- 20
- Study locations
NCT04225117 is a Phase 2 study of Locally Advanced or Metastatic Malignant Solid Tumors that is active but no longer recruiting, run by Astellas Pharma Global Development. The registered enrollment target is 329 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT04225117, a Phase 2 study of Locally Advanced or Metastatic Malignant Solid Tumors, is active but no longer recruiting, sponsored by Astellas Pharma Global Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 329 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR) per RECIST v1.1. This study will also assess other measures of antitumor activity; overall survival (OS); as well as the safety and tolerability of enfortumab vedotin for cohorts 1 to 8 and enfortumab vedotin + pembrolizumab in cohort 9.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG enfortumab vedotin
Study Locations (20)
Florida
- Florida Cancer Specialists - Fort Myers
- Florida Cancer Specialists - Tallahassee
- Florida Cancer Specialists - West Palm Beach
Georgia
- Piedmont Hospital - Atlanta
- Northside Hospital - Atlanta
Illinois
- Northwestern University Medical Center - Chicago
- University of Chicago - Chicago
Michigan
- University of Michigan - Ann Arbor
- Henry Ford Hospital - Detroit
Arizona
- Arizona Oncology - Tucson
California
- University of California - San Francisco - San Francisco
Colorado
- University of Colorado - Aurora
Indiana
- Indiana University Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2020-03-09 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04225117
The ClinicalTrials.gov registry entry for NCT04225117 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 329 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced or Metastatic Malignant Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.
NCT04225117 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT04225117 about?
NCT04225117 is a clinical study titled "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)". The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR) per RECIST v1.1. This study will also assess other measures of antitumor activity; overall survival (OS); as well as the safety and tolerability of e...
What is the current status of trial NCT04225117?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 329 participants. The study started on 2020-03-09. Estimated completion is 2026-09-30.
What conditions does trial NCT04225117 study?
This clinical trial studies the following conditions: Locally Advanced or Metastatic Malignant Solid Tumors.
What interventions are being tested in trial NCT04225117?
The interventions under investigation include: pembrolizumab (DRUG), enfortumab vedotin (DRUG).
Who is sponsoring clinical trial NCT04225117?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04225117 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced or Metastatic Malignant Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.